Please login or create an account. If you do not have access to this content, you will be shown a 30 second preview and licensing options.
- Presentation
Best Supportive Care as the Cornerstone of SJS/TEN Treatment
Description
The speaker argues that best supportive care is the cornerstone of treatment for Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN), a rare but severe drug-induced disease with high acute mortality and frequent long-term sequelae. They explain that epidermal loss causes acute skin failure with fluid, metabolic, infectious, and thermoregulatory complications, while mucosal involvement can lead to respiratory, digestive, and especially ocular damage with lasting disability. Although SJS/TEN is immunologically mediated and immunosuppressive treatments might seem promising, available studies have not shown clear reductions in mortality compared with supportive care, and evidence is limited by the rarity of the disease, inconsistent outcomes, and trial designs that exclude the sickest patients. The presenter cites retrospective studies showing no benefit of cyclosporine, corticosteroids, or IVIG over supportive care, and notes that none of the treatments in a network meta-analysis proved superior. They emphasize that specialized multidisciplinary centers and ICU expertise improve outcomes, and that mortality has decreased over time in their center largely because of improved supportive care rather than immunotherapy. The conclusion is that optimized supportive care in expert referral centers is currently the most reliable approach and may itself reduce mortality while better trials and larger registries are needed.
View moreConclusions
- Optimized best supportive care in multidisciplinary expert centers appears to be the cornerstone of SJS/TEN treatment and can reduce mortality on its own.
- No immunosuppressive or immunomodulatory drug has yet shown a consistent mortality benefit over supportive care in available studies.
- The apparent effectiveness of treatments such as cyclosporine is limited by selection bias because the sickest patients are often excluded from trials.
- Because SJS/TEN is rare and outcomes are not standardized, high-quality comparative trials are difficult to conduct and interpret.
- Supportive care should focus on correcting acute skin failure, controlling pain and anxiety, preventing and treating infection, and protecting ocular and visceral organs.
- Transfer to specialized referral or ICU-capable centers is associated with better outcomes than managing patients outside expert centers.
- Most survivors develop significant long-term sequelae, so reducing mucosal morbidity and chronic complications is an important therapeutic goal.
- Large registries and standardized supportive-care protocols are needed to better evaluate future therapies and improve trial design.
- de Prost N et al. Medicine. 2010.
- Ingen-Houz-Oro S et al. Ann Dermatol Venereol. 2021.
- Journal of Investigative Dermatology 2013 survival analysis of 460 patients with Stevens-Johnson syndrome and toxic epidermal necrolysis.#10.1038/jid.2012.510
- Health-related quality of life and long-term sequelae in survivors of epidermal necrolysis: an observational study of 57 patients. Br J Dermatol. 2019.#10.1111/bjd.18387
- Han BS et al. JAAD. 2021.
- Open trial of ciclosporin treatment for Stevens-Johnson syndrome and toxic epidermal necrolysis. Br J Dermatol. 2010.#10.1111/j.1365-2133.2010.09863.x
- Valeyrie-Allanore et al. (2010).
- Evidence for Management of Adult SJS/TEN. S. Ingen-Housz-Oro et al.
- French national protocol for diagnosis and management of epidermal necrolysis in adults (Stevens-Johnson syndrome and toxic epidermal necrolysis).#10.32388/53yqte
- Mortality trends in Stevens-Johnson syndrome and toxic epidermal necrolysis in France.